Qbtech launches breakthrough product in the US: First test cleared by FDA to provide unbiased evaluation of ADHD treatment
The US Food and Drug Administration (FDA) has cleared the neuropsychological test – QbTest – developed by the Swedish company Qbtech to aid in the evaluation of treatment interventions in patients with ADHD. QbTest is a computer-based test providing clinicians with objective and unbiased decision-making support when diagnosing and treating ADHD in children, adolescents and adults. QbTest is the only test in the world cleared by the FDA for this usage.
Approximately 145 000 patients have undergone a QbTest in Europe and the US. Traditionally, a clinical interview and subjective information from various rating scales, performed by the patient and their immediate family, teachers and others, has been the standard when evaluating treatment effects. This process is complex, involves administrative costs for the clinic and can extend the time to evaluate if the treatment is working. A further limitation is that such evaluations carry significant risk for biased feedback.  QbTest provides unbiased and objective outcome measurements that can be utilized quickly and easily and is not biased for or against medication or any other treatment.
– QbTest is the first objective test in the world to be cleared by the FDA for treatment evaluation within ADHD. This enables clinicians to better determine effects of treatment and to reduce the risk of over- and undermedication of patients, explains Carl Reuterskiöld, CEO of Qbtech. He goes on to say:
– Each patient responds differently to treatment. QbTest helps to ensure that the right patients get the right treatment faster – an outcome that can increase quality of life for patients.
A Better View of ADHD
QbTest makes it easier for clinicians to identify, rule out and monitor ADHD by providing an unbiased view of the patient’s symptoms . By adding QbTest to the clinical pathway, studies show that you can improve diagnostic accuracy, reduce the risk of unidentified ADHD and help to identify patients not responding to treatment.  , 
QbTest measures the three core signs of ADHD – hyperactivity, inattention and impulsivity – in children, adolescents and adults. QbTest is a computer-based test that combines a test of attention ability with a movement analysis based on an infrared measurement system. The test results are presented in a report and compared with norm data from a group of people of the same sex and age who do not have ADHD.
This is how QbTest works
For further enquiries, please contact:
Carl Reuterskiöld, CEO of Qbtech, tel: +46 (0) 8 790 50 01, email: email@example.com
Qbtech AB, Quantitative Behaviour Technology AB, is a privately owned Swedish company founded in 2002. Qbtech is engaged in developing solutions and products for improving the diagnosis, treatment and follow-up of patients with neuropsychiatric disorders. Qbtech has 16 employees and offices in Stockholm, Chicago, London and Frankfurt .
Epstein, N.J et al. (2006). Assessing medication effects in the MTA study using neuropsychological outcomes
. Journal of Child Psychology and Psychiatry, 47,
 Vogt, C., & Shameli, A. (2011). Assessments for attention-deficit hyperactivity disorder: use of objective measurements The Psychiatrist, 35 , 380-383.
 Vogt, C., & Williams, T. (2011). Early identification of stimulant treatment responders, partial Responders and non- responders using objective measures in children and adolescents with hyperkinetic disorder. Child and Adolescent Mental Health , 3 , 144-149.